Somatostatin in neuroblastoma and ganglioneuroma

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2084-2089

  Kogner, P ^a   Borgstrom P ^a   Bjellerup, P ^a   Chilling, F H ^c   Refai, E ^b   Jonsson, C ^b   Dominici, C ^e   Wassberg, E ^f   Bihl, H ^d   Jacobsson, H ^b   Theodorsson, E ^f   Hassan, M ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c OLGAHOSPITAL   (Germany)

^d KATHARINENHOSPITAL   (Germany)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f NONE

Author keywords

Autocrine; Ganglioneuroblastoma; Ganglioneuroma; Neuroblastoma; Neuropeptide Y; Octreotide; Prognosis; Retinoic acid; Somatostatin; Vas oactive intestinal peptide; Xenograft

Indexed keywords

ISOTRETINOIN; NEUROPEPTIDE Y; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE I 131; RETINOIC ACID;

ANIMAL MODEL; APOPTOSIS; CELL DIFFERENTIATION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; GANGLIONEUROMA; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; TUMOR SCINTISCANNING; XENOTRANSPLANTATION; ANIMAL; ARTICLE; CANCER STAGING; FOLLOW UP; GENE AMPLIFICATION; GENETICS; INFANT; METABOLISM; NUDE RAT; ONCOGENE MYC; RAT; SURVIVAL RATE; XENOGRAFT;

ANIMALS; FOLLOW-UP STUDIES; GANGLIONEUROMA; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; NEOPLASM STAGING; NEUROBLASTOMA; OCTREOTIDE; RATS; RATS, NUDE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031240821     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(97)00212-8     Document Type: Conference Paper

References (27)

1. Kogner P. Neuropeptides in neuroblastomas and ganglioneuromas. In Nyberg F, Sharma HS, Wiesenfeld-Hallin Z, eds. Progress in Brain Research, 104, Neuropeptides in the Spinal Cord. Amsterdam, Elsevier, 1995, 325-338.
2. Reichlin S. Somatostatin. New Engl J Med. 309:1984;1495-1501, 1556-1563.
3. Shulkes A. Somatostatin: physiology and clinical applications. In Fuller P, Shulkes A, eds. Ballière's Clinical Endocrinology and Metabolism, 1994, 8, 215-236.
4. Patel Y. C., Greenwood M. T., Panetta R., et al. Mini review: the somatostatin receptor family. Life Sci. 57:1995;1249-1265.
5. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 48:1988;6977-6985.
6. Lambert S. W. J., van der Lely A. J., de Herder W. W., Hofland L. J. Octreotide. New Engl J Med. 334:1996;246-254.
7. O'Dorisio M. S., Chen F., O'Dorisio T. M., Wray D., Qualman S. J. Characterization of somatostatin receptors on human neuroblastoma tumours. Cell Growth Diff. 5:1994;1-8.
8. Maggi M, Baldi E, Finetti G, et al. Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res 1994, 54, 124-133.
9. Candi E, Melino G, De Laurenzi V, et al. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 1995, 96, 141-145.
10. Moertel C. L., Reubi J. C., Scheithauer B. S., Schaid D. J., Kvols L. K. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol. 102:1994;752-756.
11. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scinitigraphy. Nucl Med Ann 1995, 1-50.
12. Sautter-Bihl M. L., Dörr U., Schilling F. H., et al. Somatostatin receptor imaging: a new horizon in the diagnostic management of neuroblastoma. Semin Oncol. 21:(13):1994;38-41.
13. Schilling FH, Kogner P, Borgström, et al. Somatostatin receptor scintigraphy (SRS) in neuroblastoma (NB): preliminary results. Med Ped Oncol 1992, 27, 332.
14. Kogner P., Björk O., Dominici C., Hedborg F., Theodorsson E. Vasoactive intestinal peptide (VIP) and somatostatin in childhood ganglioneuromas and neuroblastomas. Proc Am Soc Clin Oncol. 11:1992;371.
15. Kogner P., Theodorsson E., Björk O. Neuropeptides indicating growth, differentiation and outcome in childhood neuroblastoma and ganglioneuroma. Clin Chem Enzyme Commun. 5:1993;289-294.
16. Bjellerup P., Theodorsson E., Kogner P. Somatostatin and vasoactive intestinal peptide (VIP) in neuroblastoma and ganglioneuroma: chromatographic characterisation and release during surgery. Eur J Cancer. 31A:1995;481-485.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11, 1466-1477.
18. Efendic S., Nylén A., Roovete A., Uvnäs-Wallenstein K. Effects of glucose and arginine on the release of immunoreactive somatostatin from the isolated perfused rat pancreas. FEBS Lett. 92:1978;33-35.
19. 131I-VIP in the rat studied by gamma-camera. Nucl Med Biol. 21:1994;865-872.
20. Biedler J., Helson L., Spengler B. A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continous culture. Cancer Res. 33:1973;2643-2652.
21. Qualman S. J., O'Dorisio M. S., Fleshman D. J., Shimada H., O'Dorisio T. M. Neuroblastoma. Correlation of neuropeptide expression in tumour tissue with other prognostic factors. Cancer. 70:1992;2005-2012.
22. 1) octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 131:1994;577-581.
23. Muller J. M., Lolait S. J., Yu V. C., Sadee W., Waschek J. A. Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances. J Biol Chem. 264:1989;3647-3650.
24. Waschek J. A., Muller J. M., Duan D. S., Sadee W. Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell SH-SY5Y. FEBS Lett. 250:1989;611-614.
25. Dorisio M. S., Fleshman D. J., Qualman S. J., O'Dorisio T. M. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul Pept. 37:1992;213-226.
26. Pence J. C., Shorter N. A. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation. Arch Surg. 128:1993;591-595.
27. Agoston D. V., Colburn S., Krajniak K. G., Waschek J. A. Distinct regulation of vasoactive intestinal peptide (VIP) expression at mRNA and peptide levels in human neuroblastoma cells. Neurosci Lett. 139:1992;213-216.